Moberg Pharma announces outcome of exercise of warrants of series 2020:1
STOCKHOLM, March 31[th], 2022. The exercise period for Moberg Pharma AB's (publ)'s ("Moberg Pharma" or the "Company") warrants of series 2020:1 ended 29 March 2022. In total, 2,339,396 warrants of series 2020:1 were exercised for subscription of in total 1,169,698 ordinary shares, corresponding to a subscription rate of approximately 10.1 percent. Moberg Pharma will thereby receive proceeds of approximately SEK 7,568,000 before issue costs.Exercised warrants have been converted to interim shares (IA) until the new ordinary shares have been registered with the Swedish Companies Registration